News >

FDA Approves Duvelisib for CLL and Follicular Lymphoma

Jason M. Broderick @jasoncology
Published: Monday, Sep 24, 2018

The FDA has approved duvelisib (Copiktra) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory follicular lymphoma.

The company also noted that studies of duvelisib have shown that the most common all-grade adverse events (≥20% occurrence) in patients receiving the drug include diarrhea or colitis, neutropenia, rash, fatigue, pyrexia, cough, nausea, upper respiratory infection, pneumonia, musculoskeletal pain, and anemia.
Verastem Oncology Receives FDA Approval of COPIKTRA™ (duvelisib) Capsules. Published September 24, 2018. Accessed September 24, 2018.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication